C-C Motif Chemokine Ligand 23
CCL23proteinCCL23 recruits monocytes to sites of plaque inflammation and modulates fibrinolytic responses following thrombus formation.
Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleMonocyte recruitment chemokine; plaque inflammation and fibrinolytic activity.
Also acts inPlatelet activation
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000274736
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I28
C — confounder / Type-II35
A — assay feasibility68
E — evidence strength15
T1DI (composite)5
Specificity differential (R−C)-6.5
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Novel Insights Into the Effects of Interleukin 6 Antagonism in Non-ST-Segment-Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform.Journal of the American Heart Association · 2020 · PMID 32515246 · doi
- Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: results of the HORIZONS-AMI trial.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2014 · PMID 25130788 · doi